OPA1 and migraine disorder: Utilizing a NTG rat migraine model, systemic administration of the peripherally restricted FAAH inhibitor URB937 served to block NTG-induced hyperalgesia [66], supporting the involvement of AEA in the mitigation of migraine pain.